Slim Down Weight Loss Wellness Lyophilized Peptides Cagrilintide 5mg 10mg 15mg Retatrutide Semag Tirz for Suppression Appetite
TDS 59 Inquiries
1415456-99-3
Pharmaceutical Grade
99%
HongKong
ZLZ peptide=ZhongTuo chemical
5mg;10mg;10mg;15mg;20mg;30mg;50mg;10vials/box
2025-10-31
14B,110-64-5
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionCagrilintide is an amylin-analog, now being developed in combination with the GLP-1 agonist semaglutide to achieve sustained weight loss in persons with overweight and obesity. This drug is an investigational therapy that reduced body weight in a phase 2 trial when administered as monotherapy in participants without diabetes and with a BMI of at least 30 kg/m2 or at least 27 kg/m2 with hypertension or dyslipidaemia[1-2].Certificates
-
TDS
Basic Info-
Product Name:
Cagrilintide
Other Name:Cagrilintide;Cargliptin;Caglitide;Cagrilintide acetate;Cagrilintide peptide;Cagrilintide 5mg 10mg 15mg;Cagrilintide(Acetate form);Kagliptin
CAS No.:1415456-99-3
Molecular Weight:0
EC Number:206-141-6
Color/Form:White to off-white
Categories:
Research-
Class:
Triple agonist — GCGR, GIPR, GLP-1R
Status:Investigational (Phase 3)
Mechanism:Simultaneously activates glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Engineered from the native GIP backbone with amino acid substitutions to confer GCGR and GLP-1R activity.
EC50 (Human GCGR):5.79 nM
EC50 (Mouse GIPR):0.191 nM
EC50 (Mouse GLP1R):0.794 nM
EC50 (Mouse GCGR):2.32 nM
EC50 (Human GLP1R):0.775 nM
EC50 (Human GIPR):0.0643 nM
Source:Jastreboff AM, et al. N Engl J Med. 2023;389(6):514-526.DOI
Clinical Development:
References-
ChEMBL:DrugBank:KEGG DRUG:PubChem:Disclaimer:
Retatrutide is an investigational compound not yet approved by FDA or EMA. This listing is for industrial and laboratory research use only. Product information on ECHEMI is provided for sourcing and specification reference. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
14B,110-64-5
-
Location:
No. 998, Taizi Road, Qingyun Street, Lusong District, Zhuzhou City, Hunan Province No. 705C-35, Building 2, Huitong Jingang Lusong Clothing Logistics Distribution Center
-
Payment Terms:
TT against copy of documents,D/P,D/A,O/A,TT against B/L draft before shipment,100% TT in advance
-
Average lead Time:
5
-
Total Annual Revenue:
Less than $1 million
-
Total Employees:
11-50
-
Year of Establishment:
2023
-
Certifications:
WSY,KETETAPAN HALAL,BES,CE
-
-
Inquiry History59 Inquiries
Country Product Purchase Quantity Date Posted
United Kingdom
Cagrilintide
10 MG Jul 31, 2026
France
Cagrilintide
10 MG May 22, 2026
Australia
Cagrilintide
4 MT Mar 9, 2026
United States
Cagrilintide
15 MG Feb 25, 2026
United States
Cagrilintide
10 PCS Dec 27, 2025
United States
Cagrilintide
2 MT Dec 21, 2025
United States
Cagrilintide
100 MG Oct 28, 2025
United States
cagrilintide
2 MT Aug 8, 2025
Philippines
Retatrutide
5 MG Aug 5, 2025
China
Cagrilintide
100 G May 6, 2025
United States
cagrilintide
5 MG Feb 18, 2025
United States
Cagrilintide
3 MT Feb 7, 2025
United States
Cagrilintide
100 Nov 12, 2024
United States
Cagrillintide Lyophilized powder
100 MG Jul 4, 2024
United States
Cagrillintide Lyophilized powder
1000 MG Apr 20, 2024
United States
Cagrlintide
1 MT Jul 31, 2026
United Kingdom
cagrilintrude
20 MG Jul 21, 2026
United States
Cagrilintide
1 KG Jul 17, 2026
United States
Cagrilintide
30 MG May 26, 2026
United Kingdom
CAGRILLINTED
10 May 3, 2026 Post an enquiry for this product




